The dual GIP/GLP-1 receptor agonist redefining metabolic research. TRZ is a synthetic dual GIP/GLP-1 receptor agonist with an extensive published clinical research profile in metabolic function, insulin sensitivity, and body composition.
Key Research Areas
Dual GIP/GLP-1Insulin sensitivityMetabolic researchBody composition
Molecular Information
| Dosage | 10mg, 30mg, 60mg, 100mg per vial |
| Purity | 99%+ (HPLC & MS Verified) |
| Format | Lyophilized powder |
| Storage | Store at -20°C. Stable at room temperature for short-term shipping. |
| Reconstitution | Bacteriostatic water (for research use only) |
| Verification | NFC Blockchain Tag included |
GLP-II-TRZ is a research compound with a growing body of published literature examining its biological activity and mechanisms of action. The research summaries below are derived from publicly available peer-reviewed studies and are provided for informational purposes only.
Research Focus Areas
Dual GIP/GLP-1Insulin sensitivityMetabolic researchBody composition
Published research on GLP-II-TRZ spans multiple model systems and research frameworks. Studies have examined mechanisms at the molecular, cellular, and systemic levels. Researchers are encouraged to access primary literature through PubMed and peer-reviewed databases.
Research Disclaimer: The research summaries provided are for informational purposes only and are based on publicly available scientific literature. We do not make medical or therapeutic claims. These statements have not been evaluated by the FDA.
Every batch of GLP-II-TRZ is independently tested and shipped with a Certificate of Analysis documenting purity, identity, batch number, and testing methodology.
Testing Specifications
| Testing Method | HPLC + Mass Spectrometry |
| Purity Standard | 99%+ |
| Lab | Third-party independent laboratory (USA 🇺🇸) |
